DE69739725D1 - Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) - Google Patents
Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)Info
- Publication number
- DE69739725D1 DE69739725D1 DE69739725T DE69739725T DE69739725D1 DE 69739725 D1 DE69739725 D1 DE 69739725D1 DE 69739725 T DE69739725 T DE 69739725T DE 69739725 T DE69739725 T DE 69739725T DE 69739725 D1 DE69739725 D1 DE 69739725D1
- Authority
- DE
- Germany
- Prior art keywords
- antibodies
- identification
- antigenes
- binding interactions
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 title abstract 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 title abstract 7
- 230000003993 interaction Effects 0.000 title abstract 2
- 230000000139 costimulatory effect Effects 0.000 title 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74636196A | 1996-11-08 | 1996-11-08 | |
| PCT/US1997/019906 WO1998019706A1 (en) | 1996-11-08 | 1997-10-29 | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69739725D1 true DE69739725D1 (de) | 2010-02-11 |
Family
ID=25000516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69739725T Expired - Lifetime DE69739725D1 (de) | 1996-11-08 | 1997-10-29 | Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1007090B1 (de) |
| JP (3) | JP4048294B2 (de) |
| KR (1) | KR100510604B1 (de) |
| CN (1) | CN1198646C (de) |
| AT (1) | ATE453406T1 (de) |
| AU (1) | AU739058B2 (de) |
| BR (1) | BR9713498A (de) |
| CA (1) | CA2270922A1 (de) |
| DE (1) | DE69739725D1 (de) |
| ID (1) | ID21676A (de) |
| NO (1) | NO992212L (de) |
| RU (1) | RU2221590C2 (de) |
| WO (1) | WO1998019706A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
| US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| CN1068524C (zh) * | 1997-06-23 | 2001-07-18 | 叶庆炜 | 一种治疗顽症牛皮癣的药物 |
| EP1159300A2 (de) | 1999-02-12 | 2001-12-05 | Genetics Institute, Inc. | Humanisierte immunoglobuline gerichtet gegen b7 moleküle und behandlungsmethoden damit |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| WO2001089567A1 (en) * | 2000-05-22 | 2001-11-29 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| CA2412377A1 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| CA2436180C (en) * | 2001-01-31 | 2011-11-08 | Idec Pharmaceutical Corporation | Immunoregulatory antibodies and uses thereof |
| JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| WO2003039486A2 (en) * | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
| WO2004022594A2 (en) * | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
| WO2006012416A2 (en) * | 2004-07-20 | 2006-02-02 | Isogenis, Inc. | Specific inhibition of autoimmunity and diseases associated with autoantigens |
| CN1817909B (zh) * | 2005-02-08 | 2010-08-11 | 复旦大学 | 一种双功能融合蛋白 |
| CN100369931C (zh) * | 2005-04-07 | 2008-02-20 | 苏州大学 | 抗人b7-1分子单克隆抗体及其应用 |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
| WO2011127418A1 (en) | 2010-04-09 | 2011-10-13 | Amgen Inc. | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| JP6698276B2 (ja) * | 2012-01-16 | 2020-05-27 | アトックス バイオ リミテッド | 細菌感染の治療用の合成ペプチド |
| CZ306905B6 (cs) | 2013-06-11 | 2017-09-06 | Česká zemědělská univerzita v Praze | Způsob pro stanovení vodní hodnoty sněhu sněhové vrstvy a zařízení pro provádění tohoto způsobu |
| CN106177931B (zh) * | 2016-08-25 | 2018-02-02 | 河北浓孚雨生物科技有限公司 | 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 |
| US12234289B2 (en) | 2018-12-07 | 2025-02-25 | Ono Pharmaceutical Co., Ltd. | Immunosuppresive agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091313A (en) * | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| DD297839A5 (de) * | 1988-08-23 | 1992-01-23 | Dana Farber Cancer Institute,Us | Alpha-untereinheit des lfa-l-leukozytadhaesionsrezeptors |
| US5521288A (en) * | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
| DE122007000078I2 (de) * | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
-
1997
- 1997-10-29 AU AU51009/98A patent/AU739058B2/en not_active Ceased
- 1997-10-29 EP EP97913955A patent/EP1007090B1/de not_active Expired - Lifetime
- 1997-10-29 KR KR10-1999-7004067A patent/KR100510604B1/ko not_active Expired - Fee Related
- 1997-10-29 RU RU99112112/15A patent/RU2221590C2/ru not_active IP Right Cessation
- 1997-10-29 CA CA002270922A patent/CA2270922A1/en not_active Abandoned
- 1997-10-29 WO PCT/US1997/019906 patent/WO1998019706A1/en not_active Ceased
- 1997-10-29 DE DE69739725T patent/DE69739725D1/de not_active Expired - Lifetime
- 1997-10-29 EP EP07013357A patent/EP1878748A2/de not_active Withdrawn
- 1997-10-29 AT AT97913955T patent/ATE453406T1/de not_active IP Right Cessation
- 1997-10-29 CN CNB971812896A patent/CN1198646C/zh not_active Expired - Fee Related
- 1997-10-29 ID IDW990357D patent/ID21676A/id unknown
- 1997-10-29 JP JP52163398A patent/JP4048294B2/ja not_active Expired - Fee Related
- 1997-10-29 BR BR9713498-8A patent/BR9713498A/pt not_active Application Discontinuation
-
1999
- 1999-05-06 NO NO19992212A patent/NO992212L/no not_active Application Discontinuation
-
2007
- 2007-07-17 JP JP2007185903A patent/JP4320381B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-18 JP JP2008158896A patent/JP2009001570A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR100510604B1 (ko) | 2005-08-31 |
| EP1007090B1 (de) | 2009-12-30 |
| CN1244128A (zh) | 2000-02-09 |
| JP2001504693A (ja) | 2001-04-10 |
| RU2221590C2 (ru) | 2004-01-20 |
| JP4048294B2 (ja) | 2008-02-20 |
| BR9713498A (pt) | 2000-02-29 |
| NO992212D0 (no) | 1999-05-06 |
| WO1998019706A1 (en) | 1998-05-14 |
| JP2007330261A (ja) | 2007-12-27 |
| AU5100998A (en) | 1998-05-29 |
| CA2270922A1 (en) | 1998-05-14 |
| EP1007090A1 (de) | 2000-06-14 |
| JP2009001570A (ja) | 2009-01-08 |
| ATE453406T1 (de) | 2010-01-15 |
| EP1007090A4 (de) | 2001-03-14 |
| CN1198646C (zh) | 2005-04-27 |
| KR20000053137A (ko) | 2000-08-25 |
| AU739058B2 (en) | 2001-10-04 |
| NO992212L (no) | 1999-07-08 |
| EP1878748A2 (de) | 2008-01-16 |
| ID21676A (id) | 1999-07-08 |
| JP4320381B2 (ja) | 2009-08-26 |
| HK1025741A1 (en) | 2000-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69739725D1 (de) | Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) | |
| PT892643E (pt) | Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito | |
| MXPA02001911A (es) | Anticuerpos ctla-4 humanos y sus usos. | |
| DK0741784T3 (da) | Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler | |
| DK0955995T3 (da) | Anvendelse af komplekser til fremstilling af præparater til behandling af sensibel hud, fremgangsmåde til fremstilling af hypoallergene præparater | |
| NL300220I2 (nl) | Immunoglobuline varianten voor specifieke FC-epsilon receptoren. | |
| AU2003288675A8 (en) | Antibodies against PD-1 and uses therefor | |
| CY1105364T1 (el) | Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης | |
| FR2663217B1 (fr) | Dispositif filtrant destine a la prevention des embolies. | |
| EP0675904A4 (de) | Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch. | |
| FR2688404B1 (fr) | Dispositif de regulation hydraulique de la marche des amputes femoraux. | |
| EP1194164A4 (de) | Prion protein peptide und deren verwendung | |
| ATE88097T1 (de) | Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut. | |
| DE68918391D1 (de) | Okulare hypotensive Mittel. | |
| NZ331398A (en) | Tumor rejection antigens presented by hla-b44 molecules, and uses thereof | |
| Ha et al. | Aggressive skin allograft rejection in CD28−/− mice independent of the CD40/CD40L costimulatory pathway | |
| AU8121391A (en) | Self-sticking matrix system for the sustained transcutaneous release of piribedil | |
| DE59008012D1 (de) | Mittel zur Behandlung von Leder und Pelzen. | |
| Moulon et al. | T cell receptor transfection shows non-HLA-restricted recognition of nickel by CD8+ human T cells to be mediated by αβ T cell receptors | |
| BG102404A (en) | The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system | |
| WO2003025000A3 (en) | Peptides capable of modulating immune response | |
| FR2670079B1 (fr) | Dispositif pour la pre-taille des sarments sur les pieds de vigne dans des plantations avec palissage. | |
| ATE156711T1 (de) | Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) | |
| ES2083182T3 (es) | Empleo de esteres de aminoalcanolamidas como agentes auxiliares de elaboracion de materias sinteticas termoplasticas. | |
| Friccius et al. | Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |